The IMPROVEMENT project: first report of the global liver transplant activityDIGESTIVE AND LIVER DISEASEIF3.82024-02-010PRE
Towards a rational approach to priority in liver transplant oncologyDIGESTIVE AND LIVER DISEASEIF3.82023-09-010PRE
Liver transplantation for perihilar cholangiocarcinoma after neoadjuvant chemoradiation with brachytherapy versus stereotactic beam radiotherapy: Pretransplant toxicity and posttransplant outcomesDIGESTIVE AND LIVER DISEASEIF3.82023-09-010PRE
Tracing anti-cancer immunity in patients undergoing liver transplantation for HCC after downstaging with immunotherapyDIGESTIVE AND LIVER DISEASEIF3.82023-09-011PRE
Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programsANNALS OF ONCOLOGYIF65.42020-10-017OAAI
Preoperative predictors of long-term outcomes for resectable intrahepatic cholangiocarcinoma (iCCA): Is there a space for neoadjuvant?ANNALS OF ONCOLOGYIF65.42020-09-010OAAI
Can liver transplantation or hepatic resection achieve cure for hepatocellular carcinoma?JOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Precision medicine targeting disrupted IGF signaling in hepatoblastomaJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Increased intestinal permeability and inflammation are associated with hepatocellular carcinoma in patients with NAFLD-related liver cirrhosisJOURNAL OF HEPATOLOGYIF332018-04-011PREAI
Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liverEJSOIF2.92017-02-0152PREAI
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine TumorsAMERICAN JOURNAL OF TRANSPLANTATIONIF8.22016-10-01142OAAI
Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activityANNALS OF ONCOLOGYIF65.42016-10-010OAAI
Patients with borderline resectable colorectal cancer liver metastases (CLM): preliminary safety and activity of perioperative triplet chemotherapy plus bevacizumab (bev)ANNALS OF ONCOLOGYIF65.42016-09-010OAAI
Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinomaBRITISH JOURNAL OF SURGERYIF8.72016-03-31144PRE
DEVELOPMENT AND VALIDATION OF AN ON-LINE WEB CALCULATOR FOR SURVIVAL AFTER TRANS-ARTERIAL CHEMO-EMBOLIZATION FOR HEPATOCELLULAR CARCINOMAJOURNAL OF HEPATOLOGYIF332016-01-010PREAI
PREDICTORS OF LATE RECURRENCE AFTER LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA ON NON-ALCOHOLIC FATTY LIVER DISEASEJOURNAL OF HEPATOLOGYIF332016-01-010PREAI
DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PATIENTS UNDERGOING LIVER RESECTION FOR HEPATOCELLULAR CARCINOMAJOURNAL OF HEPATOLOGYIF332016-01-010PREAI
PREDICTING LIVER DECOMPENSATION AFTER RESECTION FOR HEPATOCELLULAR CARCINOMA: A RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORSJOURNAL OF HEPATOLOGYIF332015-04-010PREAI
Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular CarcinomaAMERICAN JOURNAL OF TRANSPLANTATIONIF8.22014-10-0153OAAI
VALUE-BASED APPROACH TO HEPATOCELLULAR CARCINOMA: OUTCOME INDICATORS TESTED IN A LARGE MULTICENTER STUDY (VBMH STUDY)JOURNAL OF HEPATOLOGYIF332014-04-010PREAI